LINCS Pilot Phase 1 Metadata Standards: RNAi Reagents
Abbreviation: LINCS 1: RNAi Reagents
This record is replaced by:
Homepage http://www.lincsproject.org/LINCS/data/previous-standards
Countries that developed this resource United States
Created in 2012
Taxonomic range
Knowledge Domains
Subjects
How to cite this record FAIRsharing.org: LINCS 1: RNAi Reagents; LINCS Pilot Phase 1 Metadata Standards: RNAi Reagents; DOI: https://doi.org/10.25504/FAIRsharing.f67zb7; Last edited: Jan. 8, 2019, 1:40 p.m.; Last accessed: Jan 18 2021 12:54 p.m.
Record added: May 18, 2016, 10:14 a.m.
Record updated:
March 28, 2017, 7:58 p.m. by The FAIRsharing Team.
online documentation | http://www.lincsproject.org/LINCS/files/ ... |
Additional Information
Contact | sherry.jenkins@mssm.edu |
No XSD schemas defined
Conditions of Use
No publications available
Reporting Guidelines
- LINCS Pilot Phase 1 Metadata Standards: Other Reagents
- LINCS Pilot Phase 1 Metadata Standards: Cell Lines
- LINCS Pilot Phase 1 Metadata Standards: Primary Cells
- LINCS Pilot Phase 1 Metadata Standards: Small Molecules
- LINCS Pilot Phase 1 Metadata Standards: Protein Reagents
- LINCS Pilot Phase 1 Metadata Standards: Antibody Reagents
Terminology Artifacts
No semantic standards defined
Models and Formats
No syntax standards defined
Identifier Schemas
No identifier schema standards defined
Metrics
No metrics standards defined
The LINCS Data Portal provides a unified interface for searching LINCS dataset packages and reagents. LINCS data are being made openly available as a community resource through a series of data releases, so as to enable scientists to address a broad range of basic research questions and to facilitate the identification of biological targets for new disease therapies. LINCS datasets consist of assay results from cultured and primary human cells treated with bioactive small molecules, ligands such as growth factors and cytokines, or genetic perturbations. Many different assays are used to monitor cell responses, including assays measuring transcript and protein expression; cell phenotype data are captured by biochemical and imaging readouts. Assays are typically carried out on multiple cell types, and at multiple timepoints; perturbagen activity is monitored at multiple doses.
This record is not implemented by any policy.
Record Maintainer
Funds
NIH Common Fund, USA (Government body)
National Institutes of Health (NIH), Bethesda, MD, USA (Government body)